{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT02950766","nct_id":"NCT02950766","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02950766. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients will undergo surgery with the intent to resect the primary kidney tumor\n\nNeovax is a combination of Poly-ICLC and Neoantigen Peptides\n\nPriming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22\n\n* In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20\n\nIpilimumab will be injected within 1 cm of each NeoVax administration","label":"Neovax in Combination with Ipilimumab","type":"EXPERIMENTAL"},{"description":"Patients will undergo surgery with the intent to resect the primary kidney tumor\n\nNeovax is a combination of Poly-ICLC and Neoantigen Peptides\n\nPriming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22\n\n* In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)","label":"NeoVax alone","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb","Oncovir, Inc."],"completion_date":{"date":"2030-05-30","type":"ESTIMATED"},"conditions":["Kidney Cancer"],"enrollment":{"count":19,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"NeoVax","otherNames":["neoantigen vaccine"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"DRUG"}],"last_update":"2026-02-03","lead_sponsor":"Patrick Ott, MD, PhD","official_title":"A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0","timeFrame":"49 days"}],"references":[{"citation":"Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Mar;639(8054):474-482. doi: 10.1038/s41586-024-08507-5. Epub 2025 Feb 5.","pmid":"39910301","type":"DERIVED"}],"start_date":{"date":"2019-03-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NeoVax Plus Ipilimumab in Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT02950766"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02950766"}